174 related articles for article (PubMed ID: 28703624)
1. Cabozantinib in the treatment of hepatocellular carcinoma.
B Peters ML; Miksad RA
Future Oncol; 2017 Sep; 13(22):1915-1929. PubMed ID: 28703624
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
Kapur S; Xiao H; Zakowski MF; Hameed MR; Levin MB
World J Oncol; 2014 Apr; 5(2):81-89. PubMed ID: 29147383
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
Scirocchi F; Napoletano C; Pace A; Rahimi Koshkaki H; Di Filippo A; Zizzari IG; Nuti M; Rughetti A
Front Oncol; 2021; 11():755433. PubMed ID: 34745989
[TBL] [Abstract][Full Text] [Related]
4. SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.
Liu C; Shi J; Lin B; Zhou M; Shan D; Nie J; Wang Y; Zhang Y; Han P; Zheng T
Curr Gene Ther; 2024 Apr; ():. PubMed ID: 36017825
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma.
Nix NM; Braun K
J Adv Pract Oncol; 2014 Jan; 5(1):47-50. PubMed ID: 25032033
[No Abstract] [Full Text] [Related]
6. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma.
Forner A; Reig M; Bruix J
Lancet; 2018 Mar; 391(10127):1301-1314. PubMed ID: 29307467
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.
Kudo M
Oncology; 2017; 93 Suppl 1():135-146. PubMed ID: 29258077
[TBL] [Abstract][Full Text] [Related]
11. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Bouattour M; Raymond E; Qin S; Cheng AL; Stammberger U; Locatelli G; Faivre S
Hepatology; 2018 Mar; 67(3):1132-1149. PubMed ID: 28862760
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
[TBL] [Abstract][Full Text] [Related]
13. The role of molecular enrichment on future therapies in hepatocellular carcinoma.
Nault JC; Galle PR; Marquardt JU
J Hepatol; 2018 Jul; 69(1):237-247. PubMed ID: 29505843
[TBL] [Abstract][Full Text] [Related]
14. NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.
Elsada A; Adler AI
Lancet Oncol; 2017 Sep; 18(9):1153-1154. PubMed ID: 28800862
[No Abstract] [Full Text] [Related]
15. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Li J; Gu J
Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
Vergote IB; Smith DC; Berger R; Kurzrock R; Vogelzang NJ; Sella A; Wheler J; Lee Y; Foster PG; Weitzman R; Buckanovich RJ
Eur J Cancer; 2017 Sep; 83():229-236. PubMed ID: 28755607
[TBL] [Abstract][Full Text] [Related]
17. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
18. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature.
Mamdani H; Wu H; O'Neil BH; Sehdev A
Discov Med; 2017 May; 23(128):331-336. PubMed ID: 28715649
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for hepatocellular carcinoma: The present and the future.
Le Grazie M; Biagini MR; Tarocchi M; Polvani S; Galli A
World J Hepatol; 2017 Jul; 9(21):907-920. PubMed ID: 28824742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
